A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

168

Participants

Timeline

Start Date

September 25, 2024

Primary Completion Date

October 25, 2024

Study Completion Date

November 7, 2024

Conditions

Healthy Participants

Interventions

DRUG

Ruxolitinib IR

Tablet

DRUG

Ruxolitinib XR

Tablet

Trial Locations (1)

Celerion Clinical Research Unit, Tempe